While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
For the first time microplastics have been found deep in the lungs of living humans. The trace materials potentially came from everyday items such as plastic bottles and bags. Dr. Jessica Shepherd, the chief medical officer at Verywell Health, joined Cheddar News to talk about the report's findings and to discuss the possible risks people might face. "The study’s most important part is we need to decrease our pollution, and we need to think about different ways to consume outside of plastic," she said.
An estimated five billion people lack access to affordable and safe surgical care around the world. For World Health Day, Cheddar News spoke with Kristie Magee Porcaro of Operation Smile, a nonprofit organization assisting with cleft lip and palate surgeries, about how they work to better it around the globe.
There has been notable disagreement in the medical community about a fourth COVID-19 vaccine dose. The FDA last week authorized a second booster dose for older and immunocompromised individuals, as some agency officials did not support the idea. The FDA made the decision without meeting with its advisory committee, as it had ahead of its recommendations on the previous COVID-19 vaccine doses.
The CDC followed in the footsteps of the FDA and authorized a fourth dose as well. Reports say the agency also did not discuss the move with its own advisory team of vaccine experts. Now, a growing number of doctors are speaking out against the decisions - leaving people confused about whether they should get another vaccine dose. Dr. Julie Morita, a member of the CDC's advisory committee to the director, and the executive vice president of the Robert Wood Johnson Foundation, joins Cheddar News' Closing Bell to discuss.
Talmon Marco, CEO of H2Pro, joins Cheddar Innovates to discuss how to bring environmentally friendly hydrogen to scale, and what this means for hydrogen's many use cases.
Catching you up on what you need to know on April 7, 2022, with updates on Ukraine urging NATO for military aid for their war with Russia, the SEC investigating Amazon, microplastics being found deep inside human lungs for the first time, and more.
Patients who have grown frustrated with lingering COVID-19 symptoms and unanswered questions are now not only the subjects of "long covid" research, but also partners in pushing this research forward. Harlan Krumholz, professor of medicine at Yale University, joins Cheddar News to discuss.
A record number of tornadoes were observed in March, topping the previous record set last year. Cheddar News speaks with NOAA’s Harold Brooks about what the implications are of an early tornado season.
Catching you up on what you need to know on April 6, 2022, with updates on the FDA’s meeting to discuss a second COVID booster shot, more on the war in Ukraine, tornadoes on the Gulf coast, a third suspect arrested in connection to the mass shooting in California, Darwin’s lost notebooks mysteriously returned, and more.
Two of naturalist Charles Darwin’s notebooks that were reported stolen from Cambridge University have been returned, two decades after they disappeared.
